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ABSTRACT
Multiple myeloma, the second most frequent hemato-
logic tumor after lymphomas, is an incurable cancer.
Recent sequencing efforts have identified the ribonu-
clease DIS3 as one of the most frequently mutated
genes in this disease. DIS3 represents the catalytic
subunit of the exosome, a macromolecular complex
central to the processing, maturation and surveil-
lance of various RNAs. miRNAs are an evolutionarily
conserved class of small noncoding RNAs, regulat-
ing gene expression at post-transcriptional level. Ri-
bonucleases, including Drosha, Dicer and XRN2, are
involved in the processing and stability of miRNAs.
However, the role of DIS3 on the regulation of miR-
NAs remains largely unknown. Here we found that
DIS3 regulates the levels of the tumor suppressor
let-7 miRNAs without affecting other miRNA fami-
lies. DIS3 facilitates the maturation of let-7 miRNAs
by reducing in the cytoplasm the RNA stability of the
pluripotency factor LIN28B, a inhibitor of let-7 pro-
cessing. DIS3 inactivation, through the increase of
LIN28B and the reduction of mature let-7, enhances
the translation of let-7 targets such as MYC and RAS
leading to enhanced tumorigenesis. Our study estab-
lishes that the ribonuclease DIS3, targeting LIN28B,
sustains the maturation of let-7 miRNAs and sug-
gests the increased translation of critical oncogenes
as one of the biological outcomes of DIS3 inactiva-
tion.
INTRODUCTION
DIS3 encodes a ribonuclease endowed with two differ-
ent RNase activities: a 3′-5′ exonucleolytic activity via the
RNase II/R (RNB) domain and an endonucleolytic activity
via the PilT N-terminal (PIN) domain (1). DIS3 is the cat-
alytic subunit of exosome, amultiprotein complex present in
both the nucleus and the cytoplasm, which plays a crucial
role in processing, quality control and turnover of a large
number of cellular RNAs (2,3). The core of the eukaryotic
exosome is composed of nine subunits that form a cylin-
dric, barrel-like structure with a prominent central channel
(2,4,5). Six of the subunits share overall structural similarity
with the bacterial phosphorolytic nuclease RNase PH and
assemble into a hexameric ring. The other three subunits
are positioned on one side of the ring and are character-
ized by S1/KH domains often found in RNA-binding pro-
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teins. The eukaryotic core-exosome displays RNA-binding
properties but lacks enzymatic activity, which is provided
by DIS3. DIS3 binds at the distal end of the barrel relative
to the S1 and KH ring and provides catalytic activity to the
entire ten-subunit complex (4,5).
Recent next-generation sequencing efforts have identified
somatic mutations in DIS3 in the hematological cancers
multiple myeloma (MM) and acute myeloid leukemia. In
MM, in particular, up to 18% of MM patients present mu-
tations affecting this gene. DIS3 mutations are located for
the most part within the major ribonuclease domains of the
protein, suggesting the mutations impair the enzymatic ac-
tivity of DIS3 (6,7). Indeed, mutant strains in yeast har-
boring nucleotide substitutions corresponding to the mu-
tations detected in human patients show growth inhibition
and changes in nuclear RNA metabolism consistent with
the dysfunction of the exosome (8). In addition in vitro as-
says have shown that yeast DIS3 mutants have a reduced
ability to exonucleolytically digest RNA substrates (8). The
reduced activity of yeast DIS3 mutants alongside genomic
data, that show how tumor cells usually retain only the
mutated copy of DIS3, suggest a role for DIS3 as a tu-
mor suppressor in multiple myeloma (7). However, how
loss-of-function DIS3 mutations are tumorigenic and how
they contribute to multiple myeloma pathogenesis remains
largely unknown.
MicroRNAs (miRNAs) are an evolutionarily conserved
class of small (18–22 nucleotides) noncoding, single
stranded RNAs that regulate gene expression at post-
transcriptional level by binding the 3′-untranslated (3′
UTR) region of mRNAs and inducing translational in-
hibition and/or degradation of their targets (9). miR-
NAs are transcribed by RNA polymerase II that produces
long primary miRNA transcripts (pri-miRNAs) that sub-
sequently undergo post-transcriptional modifications. In
the nucleus, the RNaseIII enzyme Drosha crops the pri-
miRNA into a 70 nucleotide (nt) hairpin-structured precur-
sor (pre-miRNA). Pre-miRNA is then exported to the cy-
toplasm where it is cleaved by another RNaseIII enzyme,
Dicer, that removes the ‘terminal loop region’, finally yield-
ing the mature 22 nt miRNA (10). The tight control of
miRNA biogenesis, both at the transcriptional and post-
transcriptional level, is critical for the proper functioning of
a variety of central biological processes including develop-
ment, differentiation (11) and hematopoiesis (10). Deregu-
lation of miRNA expression has been associated with mul-
tiple diseases including cancer (12,13) where a global reduc-
tion of miRNAs has been often observed as a general trait
(14–16). Notably, this repression is not due to a reduction
in the transcription of primary miRNA species, suggesting
a critical role of miRNA processing in tumorigenesis (17).
Among miRNAs, let-7 represents an important fam-
ily. It includes 12 members residing in various locations
throughout the genome that are frequently deleted in hu-
man cancers. The let-7 miRNA family members act as
tumor suppressors. They negatively regulate the transla-
tion of oncogenes and cell cycle regulators including RAS,
MYC and HMGA2 (11,18,19). let-7 miRNAs present de-
creased expression in several cancer types, and low let-7
levels correlate with poor prognosis (20,21). Conversely,
overexpression of let-7 blocks cellular proliferation, inhibits
cell growth and impairs tumor development in a xenograft
model of non-small cell lung cancer (22).
The pluripotency factor LIN28 reduces let-7 expression,
blocking its maturation (22,23). Reducing let-7, LIN28
maintains the undifferentiated and proliferative state of
stem cells (24). LIN28 is highly expressed during embryo-
genesis and then silenced in adult somatic cells. There are
two paralogues of LIN28 (LIN28A and LIN28B) struc-
turally similar but distinguishable in expression patterns,
subcellular localization and mechanism leading to let-7 in-
hibition (25–27). LIN28A acts in the cytoplasm, recruiting
a TUTase, ZCCHC11 to let-7 precursors and hampering
their processing by Dicer (28). On the contrary, LIN28B se-
questers immature let-7 transcripts in the nucleus, inhibiting
their further processing by Microprocessor (27). LIN28A
and LIN28B exert prominent roles in stem cell biology, tis-
sue development, and also in tumorigenesis (29). LIN28A
and B untimely and inappropriate re-expression has been
reported in several cancer type (29). They are often overex-
pressed in amutually exclusivemanner, and behave as onco-
genes largely through their repression of let-7miRNAs (30).
In this study, we aimed to explore and define the role of
DIS3 on miRNA biogenesis. Our findings point to a cru-
cial role for the ribonucleaseDIS3 in promoting thematura-
tion of the let-7miRNA tumor suppressor family, through a
DIS3-mediated control of the pluripotency factor LIN28B.
MATERIALS AND METHODS
Cell culture and transfections
U2OS, HEK-293T and NIH3T3 cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) and 1% of Penicillin
and Streptomycin antibiotics. RPMI-8226 and KMS12-
BM cells were cultured in RPMI medium with 10% FBS
and 1% of Penicillin and Streptomycin. To silence SKI2 and
MTR4 we used Dharmacon SMART pool siRNAs (Dhar-
macon, Lafayette, CO, USA) specific for SKI2 (cat. no. L-
013435-01-0010), forMTR4 (cat. no. L-031902-02-0010) or
a SMART pool of scrambled siRNAs (cat. no. D-001810-
01-20) as control. To overexpress miRNA let-7aU2OS cells
were transfected with miRNA mimic of let-7a (Ambion,
Naugatuck, CT, USA; cat.no. 4464066) or a miRNAmimic
negative control (cat. no. 4464058). siRNAs and miRNA
mimics were transfected in U2OS cells by lipofectamine
RNAiMAx (Invitrogen, Carlsbad, CA,USA) at a final con-
centration respectively of 30 and 33 nM according to the
manufacturer’s instructions.
Lentiviral vectors
To knockdown DIS3 expression, pLKO.1 lentiviral vectors
carrying short hairpin RNAs targeting human or murine
DIS3 were used in infection experiments. Non-targeting,
scrambled shRNA (ctrl shRNA) was used as negative con-
trol. For further details see supplementary methods.
Western blotting
The protocol, the antibodies and working dilutions are de-
scribed in details in the supplementary methods.
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RNA extraction, fractionation and qRT-PCR
Total RNA was extracted from cells using TRIzol R© RNA
Isolation Reagent (Invitrogen, Carlsbad, CA, USA) and
transcripts were quantified by q-RT-PCR using compara-
tive threshold cycle method. Further details are provided in
the supplementary methods.
mRNA and miRNA expression profiling
Total RNA from RPMI-8226 and KMS12-BM cell lines
knocked-down with a scrambled shRNA (control sh) or
DIS3 shRNA (DIS3 sh) was collected 72 h after infection
and extracted with TRIzol R© RNA IsolationReagent. Qual-
ity assessment was performed using a Bioanalyzer Agilent
2100 (Agilent, Santa Clara, CA, USA). Total RNA samples
were processed using the FlashTag labeling kit and then hy-
bridized to theGeneChip R©miRNAarrays v1.0 (Affymetrix
Inc., Santa Clara, CA, USA), according to the Affymetrix
recommended protocol. Expression values for 847 human
miRNAs were extracted from CEL files using Affymetrix
miRNA QC tool software (RMA normalized and log2-
transformed (31)). Data were analyzed using the software
dCHIP (http://biosun1.harvard.edu/complab/dchip). The
microarray data have been deposited in the Gene Expres-
sion Omnibus (GEO) under accession number GSE55246
(available at http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?token=orydwgscvrmpbaz&acc=GSE55246). Gene set
enrichment analysis (GSEA) was performed as previously
described (GSEA v2.0 at http://www.broad.mit.edu/gsea,
(32)) using gene set as permutation type and 1000 permu-
tations and signal to noise as metric for ranking genes.
miRNA families were derived from miRBase (http://www.
mirbase.org). In line with GSEA default settings, only
miRNA families including at least five members were in-
cluded in the analysis.
RNA stability assay
U2OS infected with a scrambled shRNA or a shRNA
specific for DIS3 were treated with 5,6-dichloro-
ribofuranosylbenzimidazole (DRB, 100 g/ml, Sigma, St.
Louis, MO, USA), an RNA polymerase II inhibitor. Cells
were collected at 0, 2, 3, 4 h after treatment and RNA
extracted using RNeasy microKIT (Qiagen, Hilden, Ger-
many). Reverse transcription was performed with random
primers and mRNA levels were measured by qRT-PCR.
Primers sequences are provided in Supplemental Table S3.
Cycloheximide treatment
U2OS infectedwith a scrambled shRNA, as control, or with
a shRNA specific for DIS3 were puromycin selected and, 72
h after infection, were treated with 100 g/ml of cyclohex-
imide for 0.5, 1, 2, 3 h. Cell lysates were blotted for MYC
and LaminB.
Focus formation assay
Focus formation assay of NIH3T3 cells infected with
scrambled shRNA (as control) or with shRNA specific for
DIS3 were plated at 60 000 cells for six-well, grown for 21
days, fixed and stained with crystal violet.
RESULTS
Loss of DIS3 specifically decreases let-7miRNA levels, with-
out affecting other miRNA families
To investigate the potential role of DIS3 in miRNA regula-
tion, we first exploredmiRNA changes resulting fromDIS3
inactivation. To this end, we tested five shRNAs targeting
DIS3 in HEK-293T cells and obtained a robust knockdown
with two hairpins, shRNA2 and shRNA4 (Figure 1A).
We then infected two different MM cell lines, KMS12-BM
(KMS12) and RPMI-8226 (RPMI), withDIS3 shRNA4 or
a scrambled shRNA, as control (Figure 1B). The RNA ob-
tained from these cells was then hybridized to miRNA ar-
rays, where their differential expression was assessed upon
DIS3 down-regulation. Remarkably, only a small fraction
of the miRNAs present on the platform was impacted
by DIS3 knockdown (Figure 1C). Also, to our surprise,
the number of miRNAs up-regulated after DIS3 inacti-
vation was more than compensated by the miRNAs that
were down-regulated, suggesting that DIS3 might not di-
rectly control miRNA levels. In all, four miRNAs were up-
regulated and eight were down-regulated 1.5-fold or more
in both cell lines. Intriguingly, among the miRNAs down-
regulated, there were several members of the let-7 family
(Figure 1D). To obtain a more rigorous assessment of the
miRNA families impacted byDIS3, aGene Set Enrichment
Analysis (GSEA)was performed (32). Remarkably, the only
pathway that was significantly dysregulated as a result of
DIS3 inactivationwas indeed the let-7miRNA family (NES
= 1.48, P< 0.05, FDR= 0.099, Figure 1E), with almost all
the members of this family affected by DIS3 knockdown.
Intriguingly, however, let-7 family members were down-
regulated, and not up-regulated, as it would have been pre-
dicted given the ribonuclease activity of DIS3 (Figure 1F).
To validate the array data, we chose four members of the
let-7 family (let-7a, let-7b, let-7f, let-7g) and we evaluated
the effect ofDIS3 silencing on their expression by quantita-
tive PCR (Figure 1G). Additionally, to further confirm the
miRNA array data, we performed a northern blot to visual-
ize the levels for one member of the let-7 family (let-7g), in
the same cells (Figure 1H). Consistent with the miRNA ar-
ray results, probe for let-7g detected a reduction after DIS3
silencing. To rule out that let-7 reduction was an off tar-
get effect of shRNA4, we evaluated let-7 levels upon DIS3
knockdown with the second shRNA (shRNA2). ShRNA2-
mediated silencing of DIS3 reduced the levels of all let-7
tested, as with shRNA4 (Supplementary Figure S1). All to-
gether, these data suggest that DIS3 does not pervasively
regulate miRNAs, but rather impacts only on a very limited
set of miRNAs, specifically affecting the miRNA family of
tumor suppressor let-7.
We next ascertained whether let-7 modulation by DIS3
was a mechanism specific for MM or could be extended to
unrelated cellular systems. We hence knocked down DIS3
in human osteosarcoma U2OS cells, in human kidney em-
bryonic HEK-293T cells and in mouse embryonic fibrob-
last NIH3T3 cells, using an shRNA targeting respectively
theDIS3 human (shRNA4) andDis3mouse sequence (Fig-
ure 2A). qPCR demonstrated a strong reduction for let-7a,
let-7b, let-7f and let-7g in U2OS and NIH3T3 cells, compa-
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Figure 1. DIS3 knockdown in MM cells selectively affects let-7 miRNA family. (A) Western blot to test the efficiency of five different shRNAs to silence
DIS3 in HEK-293T cell line. (B) Western blot analysis of DIS3 expression in MM cell lines, KMS12-BM (KMS12) AND RPMI-8226 (RPMI), infected
with a scrambled shRNA (ctrl) or DIS3 shRNA4 (shRNA). Lamin B was used as loading control. (C) Pie charts summarizing the number of miRNAs
deregulated >1.5-fold in KMS12 and RPMI, and in both cell lines after DIS3 knockdown. (D) Heat map showing the expression levels of miRNA
varying >1.5-fold in both KMS12 and RPMI upon DIS3 silencing. The color scale bar in the heat map represents the relative miRNA expression with
red representing up-regulation and blue representing down-regulation. (E) GSEA ES plot showing the enrichment of let-7 miRNA family gene set after
DIS3 silencing. (F) Heat map of let-7miRNA family levels in KMS12 and RPMI cell lines after infection with a scrambled shRNA (ctrl) or DIS3-specific
shRNA4 (sh). (G) Expression of the let-7miRNA members (a, b, f, g) assayed by qRT-PCR in KMS12 and RPMI cell lines infected with scrambled (ctrl)
or DIS3-specific shRNA4 (sh), 72 h after infection. Results are normalized over RNU6B. Bars represent SDs (n = 2 indipendent experiments). *P < 0.05;
**P< 0.005 using two-tailed Student’s t test. (H) Northern blot analysis of endogenous let-7g in KMS12 and RPMI cell lines infected with scrambled (ctrl)
or DIS3-specific shRNA4 (sh), 72 h after infection. RNU6B was used as loading control.
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Figure 2. let-7 levels after DIS3 knockdown in human and mouse cell lines. (A) Western blot analysis of DIS3 expression in human U2OS and HEK293T
cells, and in mouse NIH3T3 cells, 72 h after infection with scrambled (ctrl) and human or mouse DIS3-specific shRNAs (sh). Results are normalized over
loading control Lamin B and RAN. (B) Expression of the let-7 miRNA members was assayed by qRT-PCR. Results are normalized over RNU6B and
miR-16 respectively for human and mouse cells. Bars represent SDs (n = 2 indipendent experiments). *P < 0.05 using two-tailed Student’s t test.
rable to the one detected in MM cells (Figure 2B). Intrigu-
ingly, DIS3 knockdown did not affect let-7 levels in HEK-
293T cells, suggesting a different molecular wiring relative
to DIS3-mediated control on let-7, specific for this cell line.
DIS3 down-regulation increases RAS and MYC protein
levels through let-7.
Let-7 miRNAs act as tumor suppressor by reducing the
levels of oncogenes including RAS, MYC and HMGA2
(24). We therefore tested the hypothesis that let-7 reduc-
tion, mediated by DIS3 could lead to an increase in MYC
and RAS levels. The depletion of DIS3 was indeed asso-
ciated with an increase on MYC and RAS protein levels
in MM cells as well in NIH3T3 cells and U2OS cell lines
(Figure 3A and Supplementary Figure S2A). Similar results
were obtained using the second shRNA, shRNA2 (Supple-
mentary Figure S3A). We then tested whether the mRNA
levels of MYC and RAS were similarly affected by DIS3
down-regulation. Notably, no significant changes in MYC
andRASmRNA levels were detected, suggesting that DIS3
controls indirectlyMYC andRAS protein expression levels,
not through RNA modulation (Figure 3B, Supplementary
Figures S2B and S3B). To gain insight on the mechanism
responsible for this phenotype, we explored the possibility
that DIS3 could affect the stability of the proteins. To this
end, RPMI cells were treated with cycloheximide to abol-
ish mRNA translation, and MYC protein levels were de-
termined by western blotting at increasing time points af-
ter the addition of the drug, with or without DIS3 knock-
down. The kinetic ofMYCdegradationwas similar between
cells infected with DIS3 shRNA to that observed in cells
infected with a control shRNA (Figure 3C). All together,
these results imply that DIS3 does not affect the stability
of the protein but rather promotes the translation ofMYC
mRNA. It has been previous shown that let-7 regulate the
translation of their targets,more than themRNA levels (33–
35). Indeed, our results obtained on HEK-293T cells sup-
port this notion. In these cells, where let-7 levels did not
change after DIS3 knockdown (Figure 2), both the protein
and the mRNA levels ofMYC and RAS similarly remained
unchanged (Supplementary Figure S4).
To conclusively demonstrate that the increase in MYC
protein levels arising from DIS3 knockdown cells was due
to let-7 down-regulation, we over-expressed a let-7a mimic
in silenced DIS3 cells and measured MYC levels by west-
ern blot (Figure 3D). let-7 mimic abrogated the increase in
MYC protein levels induced by DIS3 knock-down, demon-
strating that DIS3 affects MYC through let-7.
Reduced let-7miRNAs correlate with increased transfor-
mation capacity in vitro (36). We then ascertained whether
DIS3 silencing could promote transformation. To this end,
a focus formation assay was performed in NIH3T3 cells.
We found thatDis3 knockdown robustly induced focus for-
mation, suggesting that Dis3 silencing is able to transform
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Figure 3. DIS3 silencing increases MYC and RAS proteins and induces transformation. (A) Representative blot and quantification of DIS3, MYC and
RAS proteins in RPMI, KMS12 and NIH3T3 cells, 72 h after infection with scrambled (ctrl) or human and mouse DIS3-specific shRNAs (sh). Results
are normalized over loading control lamin B and RAN, respectively for MM cells and NIH3T3 cells. The error bars represent SD of two independent
experiments. (B)MYC andRASmRNA levels normalized overGAPDH in the same cells of panel (A). Bars represent SDs (n= 2 indipendent experiments).
*P < 0.05; **P < 0.005. (C) U2OS infected with scrambled (ctrl) or DIS3-specific (sh) shRNAs were treated with 100 g/ml cycloheximide for the time
indicated and lysates were immunoblotted for DIS3 and MYC. Lamin B represents a loading control. (D) Western blot and quantification of levels for
endogenous DIS3 andMYC in U2OS cells knocked-down with a scrambled shRNA (ctrl) or aDIS3 specific shRNA (shRNA4, sh), 48 h after transfection
with let-7a (+) or control RNA (–) mimics. Lamin B was used as loading control. (E) Western blot of DIS3 levels and focus formation assay of NIH3T3
cells infected with scrambled shRNA (ctrl) or with murine DIS3 shRNA4 (sh). Colonies were counted from three independent platings. The error bars
represent SD. **P < 0.005 using two-tailed Student’s t test. RAN represents the loading control.
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Figure 4. DIS3 affects let-7 processing regulator LIN28B. (A) Measurement by qRT-PCR of the pri-miRNAs let-7-a/f/d (left panel) and mature miRNA
let-7-a (right panel) in RPMI, KMS12 and U2OS cells, 72 h after infection with scrambled (ctrl) or DIS3-specific shRNA (sh). pri-miRNAs let-7-a/f/d
expression data were normalized overGAPDH. let-7-a expression data were normalized overRNU6B. Bars represent SDs (n= 2 indipendent experiments).
*P< 0.05; **P< 0.005 using two-tailed Student’s t test. (B)LIN28A andLIN28BmRNA levels assessed by qRT-PCRwith respect toGAPDH expression 72
h after infection. Bars represent SDs (n= 2 indipendent experiments). **P< 0.005 using two-tailed Student’s t test. (C) Blot (left panel) and quantification
(right panel) representative for two experiments showing DIS3 and LIN28B protein levels in RPMI, KMS12 and U2OS 72 h after infection with shRNA
targeting DIS3. Lamin B was used as loading control.
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Figure 5. DIS3 controls let-7 through LIN28B. LIN28B mRNA (left
panel) and let-7-a and let-7-g (right panel) levels of one representative ex-
periment in which RPMI cells infected with a scrambled shRNA (ctrl) or
with a DIS3 shRNA4 (DIS3 sh) underwent, after 3 days, a second infec-
tion with a scrambled shRNA (ctrl) or with a LIN28B shRNA. LIN28B
and let-7 levels were measured 4 days after the second infection and nor-
malized over GAPDH and RNU6B respectively. Bars represent SDs (n =
2 replicas of one representative experiment).
fibroblasts in vitro (Figure 3E). This result was confirmed
with a second shRNA forDIS3 (Supplementary Figure S5).
DIS3 controls let-7 processing through LIN28B.
Transcriptional and post-transcriptional mechanism, in-
cluding processing andmaturation from the pri- to pre- and
mature forms, regulate miRNA levels (10). We next sought
to define whether DIS3 directly affects let-7 transcription or
is instead involved in its maturation. To this end, we com-
pared and contrasted the levels of immature pri-let-7 with
mature let-7 after DIS3 knockdown. We did not detect any
reduction in let-7 primary transcripts upon DIS3 down-
regulation, indeed even an increase, especially in KMS12
cells (Figure 4A, left panel). On the contrary, qPCR anal-
ysis demonstrated a consistent reduction in mature let-7,
in DIS3 silenced cell lines, including RPMI, KMS12 and
U2OS cells (Figure 4A, right panel). The discrepancy be-
tween reduced let-7 mature levels and unchanged or even
increased let-7 immature forms strongly suggests a role for
DIS3 on let-7 maturation. These results further imply the
existence of a negative regulatory factor inhibiting let-7 pro-
cessing in DIS3 knocked down cells.
Previous studies have demonstrated that let-7 cleavage
and maturation is under the control of the pluripotency
factor LIN28 (29). We then asked whether DIS3 down-
regulation alters the levels of LIN28A and LIN28B. qPCR
and western blot analysis revealed that the expression levels
of LIN28A and LIN28B were variable among the cell lines
tested, with KMS12 and U2OS showing the highest, and
RPMI and NIH3T3 with low basal levels (Figure 4B and C
and Supplementary Figures S6 and S7). Notwithstanding,
we found a specific increase of LIN28B both at the RNA
and at the protein level upon DIS3 knockdown, with both
shRNAs, in all cell lines where let-7was reduced uponDIS3
knock-down (Figure 4B and C and Supplementary Figures
S6–S8). Intriguingly, LIN28A, expressed at very low levels
also in basal conditions, was not affected byDIS3 silencing
suggesting that DIS3 controls let-7 through a selectivemod-
ulation of LIN28B levels (Figure 4B). Accordingly, LIN28B
levels did not change in HEK-293T cells, where let-7 levels
did not decrease upon DIS3 knockdown (Supplementary
Figure S9).
To conclusively demonstrate that LIN28B is required for
the repression of let-7 as a result of DIS3 knockdown, the
concomitant silencing of LIN28B and DIS3 was carried
out in RPMI and U2OS cells (Figure 5 and Supplemen-
tary Figures S10 and S11). We found that in both cell lines
knockdown of LIN28B completely abrogated the reduction
of mature let-7mediated byDIS3 silencing, confirming that
LIN28B is required forDIS3-mediated let-7 reduction (Fig-
ure 5 and Supplementary Figure S11, right panel).
DIS3 affects RNA stability of LIN28B.
We next investigated the relationship between DIS3 and
LIN28B. As DIS3 is the catalytic subunit of the exosome, a
complex playing a crucial role in exosome-mediated RNA
processing and decay (37) and since its silencing results in an
increase of LIN28BmRNA levels, we speculated that DIS3
could be involved in the degradation of LIN28B RNA.
To test this hypothesis, we infected U2OS cells with a
scrambled shRNA or with a shRNA specific for DIS3,
treated cells with 5,6-dichloro-ribofuranosylbenzimidazole
(DRB) to blockRNA synthesis and thenmeasured LIN28B
RNA or GAPDH (as control) levels over a 4-h time in-
terval. Upon transcriptional block, LIN28B RNA levels
were significantly more stable after DIS3 knockdown when
compared with cells infected with scrambled shRNA (Fig-
ure 6A). On the contrary GAPDHmRNA half-life was not
affected. These results indicate that DIS3 specifically con-
trols the mRNA stability of LIN28B.
It has been previously shown that exosome preferentially
degrades RNA enriched in ARE sites (38,39). AREs consist
of one or several AUUUA pentamers located in an adeno-
sine and uridine rich region (40). These elements are bound
byARE-binding proteins endowedwith RNA stabilizing or
destabilizing functions, able to modulate mRNA stability
or translation efficiency of mRNA target (40,41). Indeed,
an analysis using the AREsite tool (http://rna.tbi.univie.
ac.at/Aresite), revealed a significant enrichment of produc-
tive, accessible and conserved AU-rich elements in LIN28B
mRNA (Supplementary Figure S12). Since mRNAs con-
taining an AU-rich element (ARE) in the 3′ UTR undergo
a rapid decay in the cytoplasm (42), we hypothesized that
LIN28B degradation by the exosome occurs in the cyto-
plasm. The eukaryotic exosome associates with two ATP-
dependent regulators, the cytoplasmic SKI complex and the
nuclear TRAMP complex. Both interact with RNA sub-
strates and thread them through the internal channel of the
exosome core (43). Each complex is endowed with an heli-
case activity, provided respectively by SKI2 and MTR4, to
unwind RNA targets. To determine in which cellular com-
partment LIN28B mRNA is degraded, we blocked cyto-
plasmic or nuclear exosome activity by transfecting U2OS
with a pool of siRNAs specific for SKI2 or MTR4. Forty-
eight hours after transfection we treated cells with DRB
and measured LIN28B and GAPDH RNA levels over a 4-
h time interval (Figure 6B and C and Supplementary Fig-
ure S13). We found that the inactivation of the cytoplasmic
complex SKI increased LIN28B mRNA stability, recapitu-
lating the effect observed upon DIS3 silencing (Figure 6B).
Once again the stabilization was specific because no signif-
icant changes were observed on GAPDH mRNA half-life.
On the contrary silencing ofMTR4, the helicase included in
the nuclear complex TRAMP, did not affect the stability of
LIN28BmRNA (Figure 6C). All together these results sug-
gest that LIN28B mRNA levels are specifically controlled
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Figure 6. DIS3 affects RNA stability of LIN28B RNA. U2OS cells were infected with a scrambled shRNA (control sh) or a DIS3 shRNA (shRNA4) (A)
or were transfected with a control siRNA (ctrl) or a siRNA against SKI (B) or TRAMP (C). 3 days after infection and selection or 48 h after transfection,
cells were treated with DRB (100 g/ml) to block RNA synthesis. The stability of LIN28B and GAPDH total mRNA was measured by qRT-PCR at 0, 2,
3 and 4 h after treatment and expressed as relative abundance with respect to mRNA level at 0 h. Bars represent SDs (n= 2 indipendent experiments in A;
n = 2 replicas of one representative experiment in B and C). *P < 0.05 using two-tailed Student’s t test.
by DIS3, mostly in the cytoplasm and probably through the
recognition of ARE sites element present in the 3′ UTR.
DISCUSSION
In this study, we provide evidences that DIS3 inactivation
stimulates oncogenic signaling pathways through a down-
regulation of the tumor suppressor miRNA family let-7.
DIS3 loss selectively increases LIN28B levels, a negative
regulator of let-7maturation. The up-regulation of LIN28B
decreases mature let-7 and de-represses of downstream let-7
targets. In particular the protein levels of two critical onco-
genes,MYC andRAS, increased. Indeed, DIS3 knockdown
transformed NIH3T3 cells (Figure 7).
Curiously, in cancer, DIS3 mutations have been found in
MM and, at a lower percentage, in AML, while mutations
in this gene have not been reported in the sequencing ef-
forts ongoing in epithelial cancers, with hundreds of patient
genomes screened as of today. Nonetheless, our findings
suggest that DIS3 impacts on the let-7 pathway in cell lines
of hematopoietic and non-hematopoietic heritage, raising
MYC and RAS protein levels in both cellular contexts. One
possible explanation for the selective presence of DIS3 so-
matic mutations in haematological cancers is the prominent
role exerted byMYC, and to a lesser extent by RAS, in these
cancers. KRAS andNRAS have been recently confirmed as
the most mutated genes in MM (6,7,44,45). MYC is deeply
involved in the pathogenesis of several hematological can-
cers. In MM, in the more advanced stages, chromosomal
rearrangements juxtapose theMYC locus on 8q24 with the
IgH or IgL locus, resulting in a several-fold enhancement
of MYC transcription (46). Recently, a more general role
for MYC has been proposed during MM pathogenesis. In
fact, both mouse and human data support the notion that a
moderate increase inMYC expression would be crucial for
the transition from the pre-malignant condition of mono-
clonal gammopathy of undetermined significance (MGUS)
toward frank MM (47). Herein, we demonstrate that DIS3
silencing affect MYC protein levels without any change in
RNA levels. It would be tempting to speculate that MM
cells empower crucial oncogenes such asRAS andMYCnot
only increasing their mRNA levels, but, in selected cases,
further boosting their activity through increased transla-
tion rate. In line with our results a recent study showed that
MMSET, the histone methyltransferase translocated in up
to 15% ofMMpatients, specifically impacts onMYC trans-
lation, and not mRNA levels, through the down-regulation
of miR-126* (48). Taken together these results suggest that
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Figure 7. Proposed model on the role of DIS3 in regulating LIN28B, let-7
and MYC and RAS.
the dysregulation of MYC translation could have a strong
impact on MM pathogenesis. As such, the conventional as-
sessment of MYCRNA levels as a reliable readout of MYC
activity might not be adequate, in particular for the iden-
tification of the patient subgroups endowed with enhanced
translation.
DIS3 is the catalytic subunit of the exosome, a multi-
protein complex present both in the cytoplasm and in the
nucleus that is involved in the degradation of many RNA
species. The cytoplasmic exosome is not required for viabil-
ity and it targets normal and aberrant mRNAs, regulating
their 3′ to 5′ turnover (49,50). The activity and the role of
the nuclear exosome are less well understood. Unlike its cy-
toplasmic counterpart, it is required for viability, and it tar-
gets a broader set of RNA species, including pre-mRNAs,
pre-tRNAs, pre-rRNAs, snRNAs and snoRNAs (3,51–58).
Several studies have started to comprehensively map genes
and pathways affected by the specific inactivation of vari-
ous exosome components (59–64). However, the mechanis-
tic details by which the exosome or its subunits shape cell
physiology are largely unknown. In particular it remains
unclear whether the inactivation of the enzymatic activity
of this complex would have a pervasive impact on RNAs
and ultimately on cell physiology, or whether its activity is
channeled through specific targets and pathways, with clear
cellular outcomes. Our findings argue in favor of this second
hypothesis, given the limited influence of DIS3 on miRNAs
as a whole, and its specific effect on LIN28B and let-7 fam-
ily.
The human genome encodes three DIS3 homologues:
DIS3, DIS3L, and DIS3L2. Unlike DIS3 and DIS3L
(65), DIS3L2 is not associated with the exosome (66,67)
since it lacks the conserved N-terminal PIN and CR3 do-
mains (65,68). Surprisingly, it has been recently shown that
DIS3L2 regulates the let-7 pathway, with amechanismhow-
ever that is entirely different from the one described herein
for DIS3 (69). In fact, our data suggest that these ribonu-
cleases regulate let-7 biogenesis at two different steps, in two
different cellular compartments and with a different mech-
anism. let-7 are initially transcribed as primary transcripts
(pri-let-7) and then cleaved by the microprocessor complex
of DGR8 and DROSHA into 70- to 100-nt hairpin-shaped
precursors (pre-let-7) (70). These pre-le-7 are exported into
the cytoplasm and processed by the RNase III enzyme
Dicer to their mature form (let-7). DIS3L2 degrades uridy-
lated pre-let-7 in the cytoplasm, partnering with LIN28A.
On the contrary DIS3 modulates let-7 pathway through the
regulation of LIN28B levels, thus affecting the abundance
of primary let-7 transcripts available for microprocessor ac-
tivity. Therefore, the inactivation of DIS3L2, as reported in
Perlman syndrome and in a subset of Wilms tumors, would
have entirely different functional consequences for the cell,
when compared with the effect of DIS3. In fact, DIS3L2
knockdown results in the accumulation of uridylated pre-
let-7 with no changes in the levels of mature let-7, con-
sistent with the DIS3L2 preferential targets, pre-let previ-
ously modified (uridylated) and thus no more available for
maturation. On the contrary DIS3 silencing reduces let-7
mature levels, ultimately affecting the whole let-7 pathway
downstream, an outcome not anticipated in the presence of
DIS3L2 inactivation.
In conclusion, we reveal a novel regulation pathway of
let-7 miRNAs controlled by the exoribonuclease DIS3. We
identified LIN28B as a direct target of the enzymatic ac-
tivity of DIS3 and we demonstrated that through LIN28B
DIS3 selectively regulates a subset of critical let-7 targets
such asMYC andRAS. Future studies are warranted to de-
termine the extent to which this pathway is affected in MM
patients mutated for DIS3 and how it contributes to MM
pathogenesis.
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